You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
沃森生物(300142.SZ)決定終止“治療用重組人乳頭瘤病毒16型E7融合蛋白疫苗”的臨牀研究工作
格隆匯 08-23 20:04

格隆匯8月23日丨沃森生物(300142.SZ)公佈,由公司子公司上海澤潤生物科技有限公司(“上海澤潤”)及其子公司上海澤潤安珂生物製藥有限公司(“澤潤安珂”)聯合研發的“治療用重組人乳頭瘤病毒16型E7融合蛋白疫苗”於2016年8月收到國家藥監局批准的《藥物臨牀試驗批件》,批件號:2016L06444,註冊分類:治療用生物製品。獲得臨牀試驗批件後,上海澤潤和澤潤安珂針對本疫苗的臨牀開展了一系列的研究工作。

隨着目前公司多個重磅產品陸續進入臨牀研究和上市的關鍵時期,公司將集中精力和優勢資源全力推進已處於臨牀研究和產業化關鍵階段的13價肺炎球菌多糖結合疫苗、預防性HPV疫苗、EV71疫苗等重磅產品的研究和產業化進度,確保上述產品早日投產上市。根據公司產品研發戰略,上海澤潤將重點推進新型預防性疫苗的研發,為有效控制新產品研發風險,經公司詳細論證,決定終止“治療用重組人乳頭瘤病毒16型E7融合蛋白疫苗”的臨牀研究工作。

此次終止治療用重組人乳頭瘤病毒16型E7融合蛋白疫苗的研發不會對公司日常生產經營和其他研發項目產生影響,敬請廣大投資者謹慎決策,注意投資風險。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account